32 results on '"Ballotta L"'
Search Results
2. P596: CLINICAL IMPACT OF TP53 DISRUPTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH A BCR INHIBITOR. A CAMPUS CLL EXPERIENCE
- Author
-
Bomben, R., primary, Rossi, F. M., additional, Vit, F., additional, Bittolo, T., additional, Zucchetto, A., additional, Papotti, R., additional, Tissino, E., additional, Pozzo, F., additional, Degan, M., additional, Zaina, E., additional, Cattarossi, I., additional, Nanni, P., additional, Marasca, R., additional, Reda, G., additional, Laurenti, L., additional, Olivieri, J., additional, Chiarenza, A., additional, Ballotta, L., additional, Cuneo, A., additional, Gentile, M., additional, Morabito, F., additional, Tafuri, A., additional, Zaja, F., additional, Foà, R., additional, Di Raimondo, F., additional, Del Poeta, G., additional, and Gattei, V., additional
- Published
- 2022
- Full Text
- View/download PDF
3. Evaluation of the immune response induced by intradermal vaccination by using a needle-less system in comparison with the intramuscular route in conventional pigs
- Author
-
Ferrari, L., Borghetti, P., Gozio, S., De Angelis, E., Ballotta, L., Smeets, J., Blanchaert, A., and Martelli, P.
- Published
- 2011
- Full Text
- View/download PDF
4. A Rare Case of Coexisting Breast Cancer and Refractory Acute Myeloid Leukemia
- Author
-
Ballotta, L., Trisolini, S. M., Iori, A. P., La Rocca, U., Micozzi, A., Gentile, G., De Giacomo, T., Guarini, A., Foà, R., and Capria, S.
- Subjects
Article Subject - Abstract
The occurrence of acute myeloid leukemia (AML) within six months from a diagnosis of breast cancer (BC) is rarely reported in the literature, and it is associated with a poor prognosis. We report herein the case of a 40-year-old woman referred to our centre affected by BC and simultaneous AML. The patient proved refractory to first line therapy and achieved complete remission (CR) with a clofarabine-based regimen followed by allogeneic stem cell transplantation (ASCT). Both during salvage chemotherapy and after ASCT, the patient presented severe infectious complications ( acute cholecistytis and Nocardia pneumonia, respectively) treated with surgery, and currently she is alive in CR for both diseases after 29 months of follow-up. The case highlights the importance of a diagnostic assessment of any unexplained cytopenia in association with solid neoplasia under treatment, underlining the feasibility and priority of a timely treatment of the haematological neoplasm in order to achieve long-term survival.
- Published
- 2020
- Full Text
- View/download PDF
5. Tools from Stochastic Analysis for Mathematical Finance: A Gentle Introduction
- Author
-
Ballotta, L. and Fusai, G.
- Subjects
QA ,HG - Abstract
The idea of this document is to provide the reader with an intuitive, yet rigorous and comprehensive introduction to the main tools in stochastic analysis required in Finance to understand the modern modelling, pricing and hedging techniques. The most important models (Brownian motion, arithmetic and geometric Brownian motion, mean-reverting models, stochastic and jump processes) are considered and their properties illustrated with the help of Matlab codes and videos. We would like to emphasize that this document is very much work in progress and we would like to encourage readers to get in touch with us with feedback, comments, suggestions for additions and, of course, corrections of typos. All of these will be gratefully acknowledged in the future releases of this document.
- Published
- 2018
6. A Gentle Introduction to Value at Risk
- Author
-
Ballotta, L. and Fusai, G.
- Subjects
HG - Abstract
This paper is an introduction to the measurement of market risk in financial markets, with examples drawn mainly from commodity markets. In particular, we present the concept of VaR, its limits, the problems related to its estimation and backtesting. This is done at single asset and at portfolio level. Issues related to estimation error, measurement of portfolio risk contribution and how to cope with derivative positions are also considered. Other important issues like liquidity, operational and credit risk will not be dealt here. For a Gentle introduction to the measurement of counterparty credit risk see the companion paper by Ballotta, Fusai and Marena always available on the SSRN web site.
- Published
- 2017
7. Potential of Energy Saving of Propane Heat Pump as replacement of gas boilers with low and high temperature emitters
- Author
-
Camponeschi Corrado, Goni Maurizio, Cioffi Francesca, Dongellini Matteo, Naldi Claudia, Morini Gian Luca, Germano Luca, Genovese Filippo, Cervellati Andrea, Casolari Alessandro, Corsaro Federico, Ciancamerla Matteo, and Ballotta Luca
- Subjects
air-source heat pumps ,r290 (propane) ,global warming potential ,energy efficiency ,environmental impact ,Environmental sciences ,GE1-350 - Abstract
This work deals with the analysis of the energy performance and the environmental impact of a Heating, Ventilation and Air Conditioning (HVAC) system based on an innovative Air-to-Water electrical Heat Pump (AWHP) using propane (R290) as the refrigerant. A building of the University of Bologna located in Forlì (North of Italy) is considered for replacing a condensing gas boiler and a conventional chiller with an AWHP using R290. To evaluate the efficiency of the existing heating system and the potential savings linked to the adoption of the propane AWHP, the building energy model was created and calibrated by collecting monthly thermal and electrical consumptions as a function of the actual climate data. In this paper, the main features of the R290-based AWHP are described in detail by emphasising the device performance as a function of the operating conditions (i.e., air and water temperature and speed of the scroll compressor). A series of scenarios have been studied to evaluate the energy performance of the propane AWHP with respect to the reference scenario under various operating conditions. The results show that while the total primary energy demand increases adopting the propane AWHP with respect to the case of a gas boiler, the non-renewable primary energy fraction decreases significantly, with a dramatic increase in the renewable quote. From an economic point of view, lower annual costs are obtained by adopting a propane AWHP coupled to fan coils, mainly when the electrical heat pump is used in a thermally insulated building in which a photovoltaic system is installed.
- Published
- 2024
- Full Text
- View/download PDF
8. A Gentle Introduction to Default Risk and Counterparty Credit Modelling
- Author
-
Ballotta, L., Fusai, G., and Marena, M.
- Subjects
HG - Abstract
In this paper we introduce the reader to the basic tools for the computation of Counterparty Credit Risk such as Credit Value Adjustment and Debt Value Adjustment. We also present the effect of mitigating clauses, like netting and collateral, in reducing the credit exposure. Detailed numerical examples are presented with reference to commodity derivatives.
- Published
- 2016
9. Managing Energy Price Risk
- Author
-
Ballotta, L., Fusai, G., and Marena, Marina
- Published
- 2016
10. Monte carlo simulation of the CGMY process and option pricing
- Author
-
Ballotta, L. and Kyriakou, I.
- Subjects
HG - Abstract
We present a joint Monte Carlo-Fourier transform sampling scheme for pricing derivative products under a Carr–Geman–Madan–Yor (CGMY) model (Carr et al. [Journal of Business, 75, 305–332, 2002]) exhibiting jumps of infinite activity and finite or infinite variation. The approach relies on numerical transform inversion with computable error estimates, which allow generating the unknown cumulative distribution function of the CGMY process increments at the desired accuracy level. We use this to generate samples and simulate the entire trajectory of the process without need of truncating the process small jumps. We illustrate the computational efficiency of the proposed method by comparing it to the existing methods in the literature on pricing a wide range of option contracts, including path-dependent univariate and multivariate products.
- Published
- 2014
11. Investment Strategies and Risk Management for Participating Life Insurance Contracts
- Author
-
Ballotta, L. and Haberman, S.
- Subjects
HG - Abstract
This paper proposes an asset allocation strategy for the risk management of the broad category of participating life insurance policies. The nature of the liability implied by these contracts allows us to treat them as options written on the reference portfolio backing the policy; consequently, the valuation approach is based on classical contingent claim theory. This leads to the identification of additional safety loadings against the risk of default implied by these contracts, and the setting up of suitable investment strategies aimed at minimizing this risk. The impact on the solvency requirements for the capital of the insurer of the proposed asset allocation strategy is analyzed by means of Monte Carlo techniques. Stress testing is considered as well with respect to the key risk factors of the model, such as the equity volatility and the market interest rate. The numerical analysis shows that, for the specific policy design considered in this paper, a suitable choice of the participation rate combined with the proposed investment strategy minimizes the overall default risk of the insurance company, both in terms of probability of default and expected severit
- Published
- 2009
12. Modelling the fair value of annuities contracts: the impact of interest rate risk and mortality risk
- Author
-
Ballotta, L., Esposito, G., and Haberman, S.
- Subjects
HG - Abstract
The purpose of this paper is to analyze the problem of the fair valuation of annuities contracts. The market consistent valuation of these products requires a pricing framework which includes the two main sources of risk affecting the value of the annuity, i.e. interest rate risk and mortality risk. As the IASB has not set any specific guidelines as to which models are the most appropriate for these risks, in this note we consider a range of different models calibrated with historical data. We calculate the fair value of the annuity as a portfolio of zero coupon bonds, each with maturity set equal to the date of the annuity payments; the weights in the portfolio are given by the survival probabilities. Moreover, we focus on the additional information provided by stochastic simulations in order to define a suitable risk margin. The nature of the risk margin is one of the main key issues concerning the IASB and Solvency project.
- Published
- 2006
13. Alternative framework for the fair valuation of participating life insurance contracts
- Author
-
Ballotta, L.
- Subjects
HG - Published
- 2004
14. Pricing of guaranteed annuity conversion options
- Author
-
Ballotta, L. and Haberman, S.
- Subjects
HG - Abstract
In this note we introduce a theoretical model for the pricing and valuation of guaranteed annuity conversion options associated with certain deferred annuity pension-type contracts in the UK. The valuation approach is based on the similarity between the payoff structure of the contract and a call option written on a coupon-bearing bond. The model makes use of a one-factor Heath-Jarrow-Morton framework for the term structure of interest rates. Numerical results are investigated and the sensitivity of the price of the option to changes in the\ud key parameters is also analyzed.
- Published
- 2003
15. Modelling and valuation of guarantees in with-profit and unitised with-profit life insurance contracts
- Author
-
Haberman, S., Ballotta, L., and Wang, N.
- Subjects
HG - Published
- 2003
16. α-quantile option in a jump-diffusion economy
- Author
-
Ballotta, L.
- Subjects
HG - Abstract
In this note, we extend the analysis of the behaviour of the α-quantile option to the case of a contract’s underlying security driven by a Lévy process. To this aim, a simulation procedure based on the order statistics is implemented. The results produced are also used to study the connections between the occurring of a jump in the market and option prices. In particular, we show that, no matter the risk-neutral valuation framework chosen, the occurring of a jump affects the tails of the distribution of the functional which defines the option payoff. Since options pay a premium for the probability mass existing in the tails of such a distribution, this fact might be seen as a first key to interpret the observed biases.
- Published
- 2002
17. A note on the alpha-quantile option
- Author
-
Ballotta, L. and Kyprianou, A.E.
- Subjects
QA - Abstract
In this communication, we discuss some properties of a class of path dependent options based on the α-quantiles of Brownian motion. In particular we show that such options are well behaved in relation to standard options and comparatively cheaper than an equivalent class of lookback options.
- Published
- 2001
18. A note on α-quantile option
- Author
-
Ballotta, L. and Kyprianou, A.E.
- Subjects
GeneralLiterature_REFERENCE(e.g.,dictionaries,encyclopedias,glossaries) ,HG - Published
- 2000
19. Multivariate Lévy Models by Linear Combination: Estimation
- Author
-
Ballotta, L., Loregian, A., and Fusai, G.
- Subjects
HG - Abstract
In this paper we propose a simple and effective two-step procedure to estimate the multivariate Lévy model introduced by Ballotta and Bonfiglioli (2012). We assess our estimation approach via simulations, comparing the results with those obtained through a standard but more computationally intensive one-step maximum likelihood estimation. The proposed method is then applied to the computation of the intra-horizon Value at Risk for a portfolio of assets following the model under consideration.
20. Quanto Implied Correlation in a Multi-Lévy Framework
- Author
-
Ballotta, L., Deelstra, G., and Rayée, G.
- Subjects
HG - Abstract
In this paper we apply the multivariate construction for Lévy processes introduced by Ballotta and Bonfiglioli (2014) to propose an integrated model for the joint dynamics of FX exchange rates and asset prices. We show that the proposed construction is consistent in terms of symmetries with respect to inversion and triangulation, and provides an insight into the quanto adjustment showing that this is affected by higher order cumulants of the pure jump part of the systematic risk factor. Using the Esscher transform, we relate Quanto options to vanilla call and put options, which allows for a fast calibration method to the vanilla and the Quanto market. As Quanto products offer significant exposure to the correlation between exchange rates and asset prices, they allow access to a market implied measure of this correlation. By means of a joint calibration exercise to the CME USD denominated Quanto futures on the Nikkei 225 index and both the Nikkei 225 and USDJPY market implied volatilities, we illustrate this approach for the case in which the driving process is assumed to be a Variance Gamma process.
21. Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi
- Author
-
Laura Ballotta, Pier Luigi Zinzani, Stefano Pileri, Riccardo Bruna, Monica Tani, Beatrice Casadei, Valentina Tabanelli, Stefano Volpetti, Stefano Luminari, Paolo Corradini, Elisa Lucchini, Maria Chiara Tisi, Michele Merli, Alessandro Re, Marzia Varettoni, Emanuela Anna Pesce, Francesco Zaja, Ballotta, L., Zinzani, P. L., Pileri, S., Bruna, R., Tani, M., Casadei, B., Tabanelli, V., Volpetti, S., Luminari, S., Corradini, P., Lucchini, E., Tisi, M. C., Merli, M., Re, A., Varettoni, M., Pesce, E. A., Zaja, F., Ballotta L., Zinzani P.L., Pileri S., Bruna R., Tani M., Casadei B., Tabanelli V., Volpetti S., Luminari S., Corradini P., Lucchini E., Tisi M.C., Merli M., Re A., Varettoni M., Pesce E.A., and Zaja F.
- Subjects
BCL2 inhibition ,BCL2 protein ,peripheral T-cell lymphoma ,relapsed/refractory ,venetoclax ,Cancer Research ,Oncology ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Clinical Trial ,RC254-282 - Abstract
Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a potential therapeutic target. BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R/R PTCL after at least one previous standard line of treatment (NCT03552692). Venetoclax given alone at a dosage of 800 mg/day resulted in one complete response (CR) and two stable diseases (SDs) among 17 enrolled patients. The majority of patients (88.2%) interrupted the treatment due to disease progression. No relationship with BCL2 expression was documented. At a median follow-up of 8 months, two patients are currently still on treatment (one CR and one SD). No case of tumor lysis syndrome was registered. Therefore, venetoclax monotherapy shows activity in a minority of patients whose biological characteristics have not yet been identified.Clinical Trial Registrationwww.clinicaltrials.gov (NCT03552692, EudraCT number 2017-004630-29).
- Published
- 2021
22. Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors
- Author
-
Elisa Lucchini, Marco Merlo, Mario Ballerini, Aldostefano Porcari, Gianfranco Sinagra, Lorenzo Pagnan, Marco Rensi, Andrea Romano, Rossana Bussani, Laura Ballotta, Francesco Zaja, Lucchini, E., Merlo, M., Ballerini, M., Porcari, A., Sinagra, G., Pagnan, L., Rensi, M., Romano, A., Bussani, R., Ballotta, L., and Zaja, F.
- Subjects
Pathology ,medicine.medical_specialty ,Cancer Research ,Marginal zone lymphoma ,Case Report ,lymphoma ,030204 cardiovascular system & hematology ,03 medical and health sciences ,0302 clinical medicine ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Pericardium ,heart involvement ,PET/CT (18)F-FDG ,Extranodal lymphomas ,RC254-282 ,central nervous system relapse/progression ,diffuse large B cell lymphoma ,marginal zone lymphoma ,MRI ,primary cardiac lymphoma ,business.industry ,Primary Cardiac Lymphoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,CNS Prophylaxis ,medicine.disease ,Lymphoma ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,cardiovascular system ,business ,Diffuse large B-cell lymphoma - Abstract
Cardiac lymphomas are rare extranodal lymphomas involving primarily and secondarily the heart and/or pericardium. Here we describe three cases of cardiac involvement from lymphoma with specific peculiarities: two primary cardiac Diffuse Large B-cell Lymphomas and one secondary involvement from Marginal Zone Lymphoma (MZL). The first case highlights the issue of early CNS relapse and the possible role for CNS prophylaxis; the second case demonstrates the difficulties of interpretation and possible mistakes of different radiologic techniques adopted to evaluate cardiac involvement by lymphoma during follow-up; the third is a unique case of MZL with cardiac involvement. Our aim is to share the findings observed in these cases putting them in relation with data from the literature.
- Published
- 2021
23. A rare case of coexisting breast cancer and refractory acute myeloid leukemia
- Author
-
Anna Paola Iori, Giuseppe Gentile, Laura Ballotta, U La Rocca, Alessandra Micozzi, Anna Guarini, Robin Foà, Silvia Maria Trisolini, Saveria Capria, T. De Giacomo, Ballotta, L, Trisolini, Sm, Iori, Ap, La Rocca, U, Micozzi, A, Gentile, G, De Giacomo, T, Guarini, A, Foa, R, and Capria, S
- Subjects
Oncology ,medicine.medical_specialty ,Case Report ,030204 cardiovascular system & hematology ,acute myeloid leukemia ,Acute myeloid leukemia ,breast cancer ,infectious complications ,03 medical and health sciences ,0302 clinical medicine ,Breast cancer ,Refractory ,Internal medicine ,medicine ,Clofarabine ,Diseases of the blood and blood-forming organs ,Cytopenia ,business.industry ,Myeloid leukemia ,General Medicine ,medicine.disease ,Transplantation ,Pneumonia ,Regimen ,030220 oncology & carcinogenesis ,RC633-647.5 ,business ,medicine.drug - Abstract
The occurrence of acute myeloid leukemia (AML) within six months from a diagnosis of breast cancer (BC) is rarely reported in the literature, and it is associated with a poor prognosis. We report herein the case of a 40-year-old woman referred to our centre affected by BC and simultaneous AML. The patient proved refractory to first line therapy and achieved complete remission (CR) with a clofarabine-based regimen followed by allogeneic stem cell transplantation (ASCT). Both during salvage chemotherapy and after ASCT, the patient presented severe infectious complications ( acute cholecistytis and Nocardia pneumonia, respectively) treated with surgery, and currently she is alive in CR for both diseases after 29 months of follow-up. The case highlights the importance of a diagnostic assessment of any unexplained cytopenia in association with solid neoplasia under treatment, underlining the feasibility and priority of a timely treatment of the haematological neoplasm in order to achieve long-term survival.
- Published
- 2020
24. Serological and cellular response to mRNA-SARS-CoV2 vaccine in patients with hematological lymphoid malignancies: Results of the study "Cervax".
- Author
-
Mohamed S, Lucchini E, Sirianni F, Porrazzo M, Ballotta L, Ballerini M, De Sabbata GM, De Bellis E, Cappuccio I, Granzotto M, Toffoletto B, Fortunati I, Russignan A, Florea EE, Torelli L, and Zaja F
- Abstract
messenger RNA (mRNA)-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccines such as BNT162b2 became available in late 2020, but hematological malignancy patients (HM pts) were not evaluated in initial registration trials. We hereby report the results of a prospective, unicentric, observational study Response to COVID-19 Vaccination in hEmatological malignancies (CERVAX) developed to assess the postvaccine serological and T-cell-mediated response in a cohort of SARS-CoV2-negative HM pts vaccinated with BNT162b2. Patients with lymphomas [non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)], chronic lymphocytic leukemia (CLL), and multiple myeloma (MM); off-therapy for at least 3 months; in a watch-and-wait program; or in treatment with ibrutinib, venetoclax, and lenalidomide were included. Different time points were considered to assess the serological response to the vaccine: before the second dose (T1), at 3-6-12 months after the first dose (T2-3-4, respectively). Since March 2021, 39 pts have been enrolled: 15 (38%) NHL, 12 (31%) CLL, and 12 (31%) MM. There were 13 of the 39 pts (33%) seroconverted at T1; an increase of the serological response was registered after the second dose (T2) (22/39 pts, 56%) and maintained after 6 months (22/39 pts, 56%) and 12 months (24/39 pts, 61%) from the first dose (T3-T4, respectively). Non-serological responders at T4 were 7/39 (18%): 0/15 NHL, 1/12 MM (8%), and 6/12 CLL (50%). All of them were on therapy (one lenalidomide, three ibrutinib, and three venetoclax). SARS-CoV2-reactive T-cell analysis (interferon gamma release assays) was available since June 2022 and was evaluated at 12 months (T4) from the first dose of vaccine in 31/39 pts (79%). T-cell-mediated-responders were 17/31 (55%): most of them were NHL and MM (47%, 41% and 12% for NHL, MM, and CLL, respectively). Both serological and T-cell non-responders were represented by pts on active therapy (venetoclax/ibrutinib). During the period of observation, eight (20.5%) pts developed mild SARS-CoV2 infection; no coronavirus disease 19 (COVID-19)-related deaths or hospitalizations were registered. In conclusion, in our cohort of lymphoproliferative pts receiving BNT162b2, CLL diagnosis and venetoclax/ibrutinib seem to be related with a lower humoral or T-mediated response. Nevertheless, the efficacy of mRNA vaccine in HM pts and the importance to continue the vaccine program even in non-responders after the first dose are supported in our study by demonstrating that a humoral and T-cell-mediated seroconversion should be observed even in the subsets of heavily immunocompromised pts., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Mohamed, Lucchini, Sirianni, Porrazzo, Ballotta, Ballerini, De Sabbata, De Bellis, Cappuccio, Granzotto, Toffoletto, Fortunati, Russignan, Florea, Torelli and Zaja.)
- Published
- 2023
- Full Text
- View/download PDF
25. Role of chemotherapy in the treatment of chronic lymphocytic leukemia in the era of targeted therapies in Italy. A Campus CLL network report.
- Author
-
Ballotta L, Maccaferri M, De Paoli L, Orsucci L, Gottardi D, Chiurazzi F, Reda G, Moia R, Cuneo A, Foà R, and Marasca R
- Subjects
- Humans, Molecular Targeted Therapy, Immunotherapy, Italy, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
- Published
- 2023
- Full Text
- View/download PDF
26. Case report: Long-lasting SARS-CoV-2 infection with post-COVID-19 condition in two patients with chronic lymphocytic leukemia: The emerging therapeutic role of casirivimab/imdevimab.
- Author
-
Ballotta L, Simonetti O, D'Agaro P, Segat L, Koncan R, Martinez-Orellana P, Dattola F, Orsini E, Marcello A, Dal Monego S, Licastro D, Misin A, Mohamed S, Sbisà E, Lucchini E, De Sabbata GM, Zaja F, and Luzzati R
- Abstract
Post-coronavirus disease 2019 (post-COVID-19) condition, previously referred to as long COVID, includes a post-acute syndrome defined by the presence of non-specific symptoms occurring usually 3 months from the onset of the acute phase and lasting at least 2 months. Patients with chronic lymphocytic leukemia (CLL) represent a high-risk population for COVID-19. Moreover, the response to SARS-CoV-2 vaccination is often absent or inadequate. The introduction of monoclonal antibodies (mAbs) in the treatment landscape of COVID-19 allowed to reduce hospitalization and mortality in mild-moderate SARS-CoV-2 infection, but limited data are available in hematological patients. We here report the effective use of casirivimab/imdevimab (CI) in the treatment of two CLL patients with persistent infection and post-COVID-19 condition. Full genome sequencing of viral RNA from nasopharyngeal swabs was performed at the time of COVID-19 diagnosis and before the administration of CI. Both patients experienced persistent SARS-CoV-2 infection with no seroconversion for 8 and 7 months, respectively, associated with COVID symptoms. In both cases after the infusion of CI, we observed a rapid negativization of the nasal swabs, the resolution of post-COVID-19 condition, and the development of both the IgG against the trimeric spike protein and the receptor-binding domain (RBD) of the spike protein. The analysis of the viral genome in the period elapsed from the time of COVID-19 diagnosis and the administration of mAbs showed the development of new mutations, especially in the S gene. The genome variations observed during the time suggest a role of persistent SARS-CoV-2 infection as a possible source for the development of viral variants. The effects observed in these two patients appeared strongly related to passive immunity conferred by CI treatment permitting SARS-CoV-2 clearance and resolution of post-COVID-19 condition. On these grounds, passive anti-SARS-CoV-2 antibody treatment may represent as a possible therapeutic option in some patients with persistent SARS-CoV-2 infection., Competing Interests: Dr. LB received honoraria for giving lectures at medical meetings from AbbVie. Dr. FZ received advisory board fees or honoraria for giving lectures at medical meetings from Roche, Celgene, Janssen, Sandoz, Gilead, Novartis, AbbVie, Amgen, Sobi, Argenx, Grifols, Takeda, and BeiGene. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Ballotta, Simonetti, D’Agaro, Segat, Koncan, Martinez-Orellana, Dattola, Orsini, Marcello, Dal Monego, Licastro, Misin, Mohamed, Sbisà, Lucchini, De Sabbata, Zaja and Luzzati.)
- Published
- 2022
- Full Text
- View/download PDF
27. Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
- Author
-
Ballotta L, Zinzani PL, Pileri S, Bruna R, Tani M, Casadei B, Tabanelli V, Volpetti S, Luminari S, Corradini P, Lucchini E, Tisi MC, Merli M, Re A, Varettoni M, Pesce EA, and Zaja F
- Abstract
Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a potential therapeutic target. BLC2 inhibitor venetoclax was investigated in a prospective phase II trial in patients with BCL2-positive R/R PTCL after at least one previous standard line of treatment (NCT03552692). Venetoclax given alone at a dosage of 800 mg/day resulted in one complete response (CR) and two stable diseases (SDs) among 17 enrolled patients. The majority of patients (88.2%) interrupted the treatment due to disease progression. No relationship with BCL2 expression was documented. At a median follow-up of 8 months, two patients are currently still on treatment (one CR and one SD). No case of tumor lysis syndrome was registered. Therefore, venetoclax monotherapy shows activity in a minority of patients whose biological characteristics have not yet been identified., Clinical Trial Registration: www.clinicaltrials.gov (NCT03552692, EudraCT number 2017-004630-29)., Competing Interests: PZ has received advisory board fees from Secura Bio, Celltrion, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC Therapeutics, Incyte, and Beigene; received consultant fees from MSD, Eusapharma, and Novartis; and received speaker’s bureau fees from Celltrion, Gilead, Janssen-Cilag, BMS, Servier, MSD, TG Therapeutics, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, Incyte, and Beigene. SL has received advisory board fees from Roche, BMS/Celgene, Gilead/kite, Jannsen, Genmab, and Regeneron. MV has received advisory board fees from Janssen, Beigene, and Roche and travel expenses from Abbvie. FZ has received advisory board fees from Roche, Celgene, Janssen, Sandoz, Gilead, Novartis, Abbvie, Amgen, Sobi, Argenx, and Grifols and received honoraria for giving lectures to medical meetings from Celgene, Janssen, Gilead, Novartis, Roche, Amgen, Abbvie, and Grifols. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Ballotta, Zinzani, Pileri, Bruna, Tani, Casadei, Tabanelli, Volpetti, Luminari, Corradini, Lucchini, Tisi, Merli, Re, Varettoni, Pesce and Zaja.)
- Published
- 2021
- Full Text
- View/download PDF
28. Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma.
- Author
-
Bega G, Olivieri J, Riva M, Scapinello G, Paolini R, Finotto S, Sartori R, Lucchini E, Guandalini G, Facchinelli D, Tisi MC, Basso M, Ballotta L, Piazza F, Ferrarini I, and Visco C
- Abstract
Background: Rituximab plus bendamustine (BR), and rituximab, bendamustine, and cytarabine (R-BAC) are well-known induction therapies in elderly patients with mantle cell lymphoma (MCL), according to clinical guidelines. However, a direct comparison between the two regimens has never been performed., Methods: In this multicentre retrospective study, we compared the outcome of patients with newly diagnosed MCL, treated with BR or R-BAC. Primary endpoint was 2-year progression-free survival (PFS). Inclusion bias was assessed using a propensity score stratified by gender, age, MCL morphology, and MIPI score., Results: After adjusting by propensity score, we identified 156 patients (53 BR, 103 R-BAC) with median age of 72 (53-90). Median follow-up was 46 months (range 12-133). R-BAC was administered in a 2-day schedule or with attenuated dose in 51% of patients. Patients treated with R-BAC achieved CR in 91% of cases, as compared with 60% for BR ( p < 0.0001). The 2-year PFS was 87 ± 3% and 64 ± 7% for R-BAC and BR, respectively ( p = 0.001). In terms of toxicity, R-BAC was associated with significantly more pronounced grade 3-4 thrombocytopenia than BR (50% vs. 17%)., Conclusions: This study indicates that R-BAC, even when administered with judiciously attenuated doses, is associated with significantly prolonged 2-year PFS than BR in elderly patients with previously untreated MCL.
- Published
- 2021
- Full Text
- View/download PDF
29. Case Report: Cardiac Involvement by Lymphoma: Rare but Heterogeneous Condition With Challenging Behaviors.
- Author
-
Lucchini E, Merlo M, Ballerini M, Porcari A, Sinagra G, Pagnan L, Rensi M, Romano A, Bussani R, Ballotta L, and Zaja F
- Abstract
Cardiac lymphomas are rare extranodal lymphomas involving primarily and secondarily the heart and/or pericardium. Here we describe three cases of cardiac involvement from lymphoma with specific peculiarities: two primary cardiac Diffuse Large B-cell Lymphomas and one secondary involvement from Marginal Zone Lymphoma (MZL). The first case highlights the issue of early CNS relapse and the possible role for CNS prophylaxis; the second case demonstrates the difficulties of interpretation and possible mistakes of different radiologic techniques adopted to evaluate cardiac involvement by lymphoma during follow-up; the third is a unique case of MZL with cardiac involvement. Our aim is to share the findings observed in these cases putting them in relation with data from the literature., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Lucchini, Merlo, Ballerini, Porcari, Sinagra, Pagnan, Rensi, Romano, Bussani, Ballotta and Zaja.)
- Published
- 2021
- Full Text
- View/download PDF
30. Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia.
- Author
-
Serrao A, Ballotta L, Dragoni F, Pallotta A, and Chistolini A
- Subjects
- Anticoagulants therapeutic use, Humans, Thrombophilia complications, Thrombophilia drug therapy, Venous Thromboembolism drug therapy, Venous Thromboembolism prevention & control
- Published
- 2020
- Full Text
- View/download PDF
31. BEAM conditioning regimen ensures better progression-free survival compared with TEAM but not with FEAM in lymphoma patients undergoing autologous stem cell transplant.
- Author
-
Marchesi F, Capria S, Pedata M, Terrenato I, Ballotta L, Riccardi C, Papa E, Riemma C, Trisolini S, Celentano M, Regazzo G, Ferrara F, Mengarelli A, and Picardi A
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carmustine, Cytarabine, Etoposide, Humans, Melphalan, Progression-Free Survival, Stem Cell Transplantation, Transplantation Conditioning, Transplantation, Autologous, Hematopoietic Stem Cell Transplantation, Lymphoma therapy
- Published
- 2020
- Full Text
- View/download PDF
32. Current and future therapeutic approaches for the treatment of follicular lymphoma.
- Author
-
Pulsoni A, Cappelli LV, Ballotta L, Canichella M, Serrao A, Annechini G, D'Elia GM, and Foà R
- Subjects
- Antineoplastic Agents administration & dosage, Antineoplastic Agents pharmacology, Drug Development methods, Humans, Lymphoma, Follicular pathology, Neoplasm Staging, Precision Medicine methods, Prognosis, Quality of Life, Watchful Waiting, Immunotherapy methods, Lymphoma, Follicular therapy, Molecular Targeted Therapy
- Abstract
Introduction: Recent advances in prognostication as well as management of Follicular Lymphoma (FL) are moving to personalized approach. Areas covered: Prognostic scores as well as consolidated and innovative therapeutic approaches are evaluated according to the various presentation modalities. For asymptomatic, low-tumor burden FL, a 'watch and wait' policy is currently the first-choice approach, although possible alternatives are discussed. Early stage FL may be treated with local radiotherapy although the role of minimal residual disease in possible additional agents should be determined. The first line treatment for symptomatic FL is chemo-immunotherapy followed by two years maintenance therapy with anti-CD20 monoclonal antibodies. A deeper knowledge of FL biology has opened new perspectives regarding the timing of therapy and has offered new targets for the development of novel agents that aim to change the therapeutic scenario of FL management. Expert commentary: The introduction of novel agents could question the incurability of FL and change the therapeutic goal from prolonging the complete remission state to eradicating the disease in young/fit patients, as well as improving quality of life in elderly/unfit patients. In the near future, combining new biologic agents and adoptive cell therapies could help in achieving these aims.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.